Literature DB >> 23159815

The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites.

David Cella1, Nikki Neubauer, Jay Thomas, Jean Kutner, Michael V Seiden.   

Abstract

OBJECTIVE: The objectives of this study are to assess the clinical relevance and validity of the Functional Assessment of Chronic Illness Therapy-Ascites Index (FACIT-AI) in women with ovarian cancer and malignant ascites, and to modify the instrument guided by qualitative feedback from patients with recurrent malignant ascites.
METHODS: Fourteen adult female patients with recurrent symptomatic malignant ascites were enrolled from three centers. All completed an open-ended symptom list to identify their primary concerns regarding their condition. They then completed a draft 10-item FACIT-AI questionnaire created from expert input. Eleven patients provided comments regarding the FACIT-AI questionnaire using a written feedback format. Three patients participated in a "think-aloud" cognitive debriefing interview to ensure patient comprehension of questionnaire items.
RESULTS: Of the first 11 patients surveyed, 7 believed that the draft FACIT-AI contained all important symptoms associated with malignant ascites. Responses from the remaining 4 patients revealed three symptoms that 2 or more patients nominated for inclusion: urinary frequency, constipation and emotional distress. These items were added to the original FACIT-AI to produce a 13-item index of symptoms associated with malignant ascites.
CONCLUSIONS: The 13-item FACIT-AI has content validity among women with malignant ascites associated with ovarian cancer. It is available for use in clinical research or practice, with the expectation that more will be learned about its performance and interpretation over time.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23159815     DOI: 10.1016/j.ygyno.2012.11.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Urinary functional outcomes in female neobladder patients.

Authors:  Georg Bartsch; Siamak Daneshmand; Eila C Skinner; Sumeet Syan; Donald G Skinner; David F Penson
Journal:  World J Urol       Date:  2013-12-07       Impact factor: 4.226

3.  Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.

Authors:  Myrte Neijenhuis; Tom J G Gevers; Thomas D Atwell; Tim J Gunneson; Amanda C Schimek; Wietske Kievit; Joost P H Drenth; Patrick S Kamath
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

4.  Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.

Authors:  Christian Martin Kurbacher; Olympia Horn; Jutta Anna Kurbacher; Susanne Herz; Ann Tabea Kurbacher; Ralf Hildenbrand; Reinhardt Bollmann
Journal:  Oncologist       Date:  2015-09-28

5.  Reliability and Validity of the Chinese Version of FACIT-AI, a New Tool for Assessing Quality of Life in Patients with Malignant Ascites.

Authors:  Yanni Lou; Linghui Lu; Yuan Li; Meng Liu; Jason M Bredle; Liqun Jia
Journal:  J Palliat Med       Date:  2015-07-15       Impact factor: 2.947

6.  Management of non-ovarian cancer malignant ascites through indwelling catheter drainage.

Authors:  Xiaoli Gu; Yuanyuan Zhang; Menglei Cheng; Minghui Liu; Zhe Zhang; Wenwu Cheng
Journal:  BMC Palliat Care       Date:  2016-04-21       Impact factor: 3.234

7.  Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.

Authors:  Weiwei Zhang; Kejun Liu; Bin Ye; Guolin Hu; Kelei Zhao; Yazhou Ren; Weijiang Liang
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

8.  Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.

Authors:  Tuanhe Sun; Kang Li; Gang Xu; Kun Zhu; Qiong Wang; Chengxue Dang; Dawei Yuan
Journal:  World J Surg Oncol       Date:  2021-07-06       Impact factor: 2.754

9.  Management of drainage for malignant ascites in gynaecological cancer.

Authors:  Chumnan Kietpeerakool; Siwanon Rattanakanokchai; Nampet Jampathong; Jatupol Srisomboon; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.